Analyst Ratings For Jazz Pharmaceuticals (NASDAQ:JAZZ)
Today, Bank of America raised its price target on Jazz Pharmaceuticals (NASDAQ:JAZZ) to $170.00 per share.
Some recent analyst ratings include
- 1/16/2018-B. Riley Reiterated Rating of Buy.
- 1/2/2018-Leerink Swann initiated coverage with a Outperform rating.
- 12/25/2017-Wells Fargo & Co Reiterated Rating of Buy.
- 12/10/2017-Cantor Fitzgerald Reiterated Rating of Buy.
Recent Insider Trading Activity For Jazz Pharmaceuticals (NASDAQ:JAZZ)
Jazz Pharmaceuticals (NASDAQ:JAZZ) has insider ownership of 4.30% and institutional ownership of 89.28%.
- On 2/14/2018 Michael Patrick Miller, EVP, sold 200 with an average share price of $139.99 per share and the total transaction amounting to $27,998.00.
- On 1/16/2018 Matthew P. Young, CFO, sold 700 with an average share price of $152.16 per share and the total transaction amounting to $106,512.00.
- On 1/12/2018 Bruce C. Cozadd, CEO, sold 3,000 with an average share price of $150.00 per share and the total transaction amounting to $450,000.00.
- On 1/12/2018 Michael Patrick Miller, EVP, sold 200 with an average share price of $148.65 per share and the total transaction amounting to $29,730.00.
- On 12/11/2017 Michael Patrick Miller, EVP, sold 200 with an average share price of $139.15 per share and the total transaction amounting to $27,830.00.
- On 12/11/2017 Patrick G. Enright, Director, sold 9,000 with an average share price of $139.73 per share and the total transaction amounting to $1,257,570.00.
- On 11/17/2017 Iain Mcgill, SVP, sold 8,000 with an average share price of $133.42 per share and the total transaction amounting to $1,067,360.00.
Recent Trading Activity for Jazz Pharmaceuticals (NASDAQ:JAZZ)
Shares of Jazz Pharmaceuticals closed the previous trading session at 145.96 up +0.20 0.14% with 143.94000244140625 shares trading hands.